What is the glow peptide stack?

It is an informal label rather than a defined product or protocol. In common use it names GHK-Cu together with BPC-157 and TB-500: three research compounds whose published work includes skin, wound and tissue-repair endpoints. No standards body defines the term, the exact list varies between the people using it, and no study has tested those three compounds as a set. Treat it as a naming convention that groups three separate research records, not as a validated combination.

What does the research say about GHK-Cu and skin?

GHK-Cu has the deepest skin record of the three. It stimulated collagen synthesis in human fibroblast cultures at very low concentrations, starting near 10^-12 molar (Maquart et al., FEBS Lett 1988, PMID 3169264), and later laboratory work reported increased collagen and elastin production at 0.01 to 100 nanomolar (Badenhorst et al., J Aging Sci 2016). Twelve-week topical human trials reported denser, firmer skin with reduced line depth (Leyden et al. and Abdulghani et al., as summarized in Pickart and Margolina, Int J Mol Sci 2018, PMID 29986520). Those describe study results, not a guaranteed outcome for any individual, and the human work was topical.

Does BPC-157 have skin research behind it?

Some, and it is thinner than its tendon and gut record. A review of BPC-157 and wound healing describes activity across repair models but is dominated by animal work with very limited human skin data (Seiwerth et al., Front Pharmacol 2021). The proposed mechanism relevant to skin is angiogenic signaling through the VEGF receptor 2 and nitric oxide pathway (Sikiric et al., Gut Liver 2020). A systematic review of BPC-157 in orthopedic sports medicine found the same overall picture: an evidence base dominated by animal studies with minimal human data (Vasireddi et al., 2025).

Why is TB-500 in a skin stack?

Because the dermal wound-healing work on thymosin beta-4 is the reason it gets grouped here. In a rat full-thickness wound model, thymosin beta-4 increased reepithelialization by 42 percent at 4 days and by as much as 61 percent at 7 days versus saline controls, with greater wound contraction, increased collagen deposition and increased angiogenesis, and it stimulated keratinocyte migration in a Boyden chamber assay (Malinda et al., J Invest Dermatol 1999). A later review frames dermal use among the applications for thymosin beta-4 while noting they remain grounded in preclinical and early-stage data (Goldstein et al., 2012). This is a rodent and cell record, not a human one.

Is KLOW the glow stack in one vial?

Close, but not the same set, and the difference is worth knowing before ordering. KLOW is a four-peptide research blend in a single 80mg vial: BPC-157, TB-500, GHK-Cu and KPV. It contains all three compounds the label conventionally names, plus KPV, a melanocortin-derived tripeptide. So KLOW is the assembled version of the convention with a fourth component added rather than an exact match to it.

Has anyone studied these compounds together?

Not in the published work behind this page. Every source in the reference list studies a single compound, so there is no combination result to report, no interaction described, and no basis for claiming the group outperforms any one of them. Grouping compounds that each have some skin-adjacent research is a rationale for asking the question. It is not an answer.

What dose does research report for a glow stack?

This page does not provide dosing. Concentrations that appear above are the conditions inside a named laboratory study, not quantities for a person, and there is no established human dose for any of these compounds. Route matters too: the strongest human GHK-Cu signal comes from topical trials, which does not transfer to another route. Any decision about a research compound belongs with a qualified clinician.

Are there cautions with the copper peptide?

Yes, and the route matters. The reported topical GHK-Cu side effects are local and generally mild, such as transient redness, stinging or occasional contact sensitivity at the application site, and there are no large human trials establishing a full systemic safety profile for injected or high-dose GHK-Cu. People with a copper allergy or a copper-metabolism disorder such as Wilson disease should avoid GHK-Cu, and by extension any blend containing it, including KLOW. Angiogenesis appears in the reported mechanism for BPC-157 and thymosin beta-4, so anyone with active cancer or a cancer history should discuss that mechanism with a physician first, and there is no safety data supporting use in pregnancy or breastfeeding. None of these compounds is approved for human use, and this is educational information rather than a safety assessment for any individual.

Research explainer

The Glow Peptide Stack

The short answer

Glow stack is a community label, not a defined protocol. It usually names GHK-Cu alongside BPC-157 and TB-500, three research compounds that each have separately published skin or wound-repair findings. Nobody has studied the three as a set, the evidence behind them is mostly cell and animal work, and the strongest human signal belongs to GHK-Cu from topical trials. The assembled product people are usually pointed at is KLOW, which contains all three plus KPV, so it is a four-peptide blend rather than an exact match to the convention.

General educational information, research-use framing only, not medical advice. Everything below is an endpoint some study reported, in the system it was reported in. None of it is a promised result, and no dose or protocol is provided here.

The term

What the glow stack refers to

The phrase came out of community shorthand rather than any laboratory, and it is worth being blunt about that before going further. There is no published definition, no standards body behind the name, and no agreed list: what stays constant across versions is GHK-Cu, and what usually joins it is BPC-157 and TB-500. That grouping has a logic to it. All three have research records that touch skin or wound repair, and they touch it through different reported mechanisms.

What the grouping does not have is a study of itself. Each compound below is summarized from its own published work, with the study system named alongside the finding, because the difference between a fibroblast culture, a rodent wound and a topical human trial is the difference between three very different strengths of claim.

GHK-CuThe copper tripeptide the label is really built around

Stimulated collagen synthesis in human fibroblast culture at very low concentrations, and later work reported increased collagen and elastin in the same kind of system

Study system: Fibroblast culture, in vitro (Maquart et al., 1988; Badenhorst et al., 2016)

BPC-157Included for its wound and soft-tissue repair record

Wound-healing activity across repair models, with angiogenic signaling described through the VEGF receptor 2 and nitric oxide pathway

Study system: Review of animal models, with very limited human skin data (Seiwerth et al., 2021; Sikiric et al., 2020)

TB-500Included for the dermal wound-healing work on thymosin beta-4

Increased reepithelialization and wound contraction versus saline controls, and stimulated keratinocyte migration

Study system: Rat full-thickness wound model and cell assay, preclinical (Malinda et al., 1999)

Compound one

GHK-Cu carries most of the skin evidence

GHK-Cu is a copper tripeptide, and it is the reason the grouping exists at all. The foundational result is old and specific: GHK-Cu stimulated collagen synthesis in human fibroblast cultures at very low concentrations, starting near 10^-12 molar (Maquart et al., FEBS Lett 1988). Later laboratory work reported increased collagen and elastin production at 0.01 to 100 nanomolar (Badenhorst et al., J Aging Sci 2016). Both are cell findings.

Beyond collagen, the research describes several linked actions. Pollard et al. (Arch Facial Plast Surg 2005) studied normal and radiation-damaged human dermal fibroblasts and reported that at 1 nanomolar GHK-Cu raised basic fibroblast growth factor and vascular endothelial growth factor in the damaged cells. Pickart et al. (BioMed Res Int 2015) report GHK signaling across skin regeneration and remodeling-related gene expression, including the proteoglycan decorin and epidermal stem cell markers such as p63 and integrins in skin-equivalent models at low micromolar concentrations. Read a broad gene signal as evidence of activity, not as a promised clinical result.

The human data exists and is narrower than it is usually made to sound. Twelve-week topical trials reported denser, firmer skin with reduced line depth (Leyden et al. and Abdulghani et al., as summarized in Pickart and Margolina, Int J Mol Sci 2018). Those were topical studies measuring appearance and skin metrics over about three months. That is a real human signal and it is ahead of compounds resting on animal data alone. It is also not the same tier of evidence as a large multicenter drug trial, and it describes study results rather than a guaranteed outcome for any individual. The full breakdown is on GHK-Cu for skin.

Compound two

BPC-157 is a repair peptide with thin skin-specific data

BPC-157 earns its place through general repair rather than through dermatology. A review of BPC-157 and wound healing describes activity across wound and repair models but is dominated by animal work with very limited human skin data (Seiwerth et al., Front Pharmacol 2021), and a separate review places the compound in the tissue-repair category across tendon, ligament and soft-tissue models (Gwyer, Wragg & Wilson, Cell Tissue Res 2019). The mechanism most relevant to skin is angiogenic: BPC-157 signaling is described through the VEGF receptor 2 and nitric oxide pathway (Sikiric et al., Gut Liver 2020), and new vessel formation is part of how any wound closes.

The caveat is the same one that applies to the compound generally. A systematic review of BPC-157 in orthopedic sports medicine found the evidence base dominated by animal studies with minimal human data (Vasireddi et al., 2025). Whatever BPC-157 contributes to a skin-focused grouping is inferred from repair biology in animals, not measured on human skin.

Compound three

TB-500 has the most directly dermal animal result

TB-500 is a synthetic peptide based on the active region of thymosin beta-4, and the study that keeps it in skin conversations was published in a dermatology journal. In a rat full-thickness wound model, thymosin beta-4 increased reepithelialization by 42 percent at 4 days and by as much as 61 percent at 7 days versus saline controls, with greater wound contraction, increased collagen deposition and increased angiogenesis; the same work reported that it stimulated keratinocyte migration in a Boyden chamber assay (Malinda et al., J Invest Dermatol 1999). Keratinocyte migration is the cell behavior behind a wound edge closing, which links the outcome back to the mechanism.

That mechanism is actin sequestration: thymosin beta-4 binds actin monomers in a 1:1 complex that inhibits polymerization (Safer, Elzinga & Nachmias, 1991), which governs how a cell changes shape and crawls toward a wound edge (Goldstein, Hannappel & Kleinman, 2005). A later review frames dermal use among the applications for thymosin beta-4 across ulcerated tissue, corneal, dermal and cardiac settings, while noting these remain grounded in preclinical and early-stage data (Goldstein, Hannappel, Sosne & Kleinman, 2012). Human clinical evidence for TB-500 in tissue healing is limited, and no large randomized trials support the recovery claims commonly attached to it.

What this does not establish

Three separate records are not one combined result

Every source on this page examines one compound. None tested the group, so there is no combination endpoint to quote and no reported interaction between them. The honest reading is three parallel research records that happen to overlap on wound and matrix biology, assembled into a name by people rather than by a study.

Model, not person

Most of the findings above come from fibroblast cultures and rodent wounds. Those are reasons to keep studying a compound, not results transferable to a reader.

Route matters

The strongest human GHK-Cu evidence is topical. A finding obtained by one route does not carry over to another, and the trials measured skin metrics over roughly twelve weeks.

Not approved

None of these compounds is FDA-approved for human use. They are sold for research use, and nothing here is a treatment claim or a protocol.

The assembled version

KLOW contains four peptides, not three

The product people are usually pointed toward is KLOW, a four-peptide research blend in a single 80mg vial: BPC-157, TB-500, GHK-Cu and KPV. It holds all three compounds the glow label conventionally names, in one vial and one reconstitution, plus a fourth. Calling it the glow stack in a vial is close enough to be useful and wrong enough to be worth correcting, because the fourth component changes what is in the bottle.

KPV is the C-terminal tripeptide of alpha-MSH, studied for anti-inflammatory signaling. Its research record here is intestinal rather than dermal: it reduced NF-kB and MAPK activation and lowered inflammatory cytokine output in intestinal cell and mouse colitis models (Kannengiesser et al., Inflamm Bowel Dis 2008), and PepT1-mediated uptake reduced colonic inflammation in mouse colitis models (Dalmasso et al., Gastroenterology 2008). That is anti-inflammatory evidence in the gut, and it should not be restated as a skin result just because it arrives in a blend sold for skin and recovery.

Running the compounds separately is the other route, and it is a trade rather than an upgrade. Singles keep each compound independent and let a GHK-Cu-led approach stay GHK-Cu-led, at the cost of separate vials, separate reconstitutions and separate storage; our GHK-Cu is supplied as 100mg per vial. A blend fixes the ratio at manufacture and collapses all of that into one vial. Neither arrangement has combination evidence behind it.

KLOW Combo →What each of the four peptides does →GHK-Cu on its own →

Reported cautions

The copper component has a specific exclusion

Be precise about which route the tolerability data covers, because the two are not interchangeable. What research reports is topical: the reported topical GHK-Cu side effects are local and generally mild, such as transient redness, stinging or occasional contact sensitivity at the application site. There are no large human trials establishing a full systemic safety profile for injected or high-dose GHK-Cu, so anything beyond the topical picture is a reported observation rather than settled clinical fact. The specific exclusion worth naming is copper: people with a copper allergy or a copper-metabolism disorder such as Wilson disease should avoid GHK-Cu, and that carries through to any blend containing it, KLOW included.

Two further cautions travel with this group because they follow from the mechanisms rather than from a side-effect report. Angiogenesis appears in the reported mechanism for BPC-157 and for thymosin beta-4, so the caution published alongside these compounds on this site is that anyone with active cancer or a cancer history should discuss that mechanism with a physician first. And there is no safety data supporting use in pregnancy or breastfeeding. All of this restates published cautions rather than assessing safety for any individual, and none of these compounds is approved for human use.

Keep reading

The compounds separately, the blend, and the skin evidence

GHK-Cu for skin

The copper peptide skin record in full, study by study.

KLOW Combo

The four-peptide blend: BPC-157, TB-500, GHK-Cu and KPV in one vial.

Best peptides for skin

Compounds with skin-relevant research, ranked by what is behind them.

BPC-157 and TB-500 stack

The repair pairing inside this group, and its evidence gap.

Copper peptides

What copper peptides are and why GHK-Cu is the one that gets studied.

KPV

The fourth component of KLOW, and the research behind it.

Glow peptide stack: FAQ

References

Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343-346. doi:10.1016/0014-5793(88)80509-x. PMID 3169264.
Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID 29986520. PMCID PMC6073405. (Summarizes the Leyden facial and eye-cream trials and the Abdulghani thigh-skin comparison.)
Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108. PMID 26236730. PMCID PMC4508379.
Pollard JD, Quan S, Kang T, Koch RJ. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Archives of Facial Plastic Surgery. 2005;7(1):27-31. doi:10.1001/archfaci.7.1.27. PMID 15655171.
Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. Journal of Aging Science. 2016;4:166. doi:10.4172/2329-8847.1000166.
Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021;12:627533. doi:10.3389/fphar.2021.627533.
Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8.
Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver. 2020;14(2):153-167. doi:10.5009/gnl18490. PMID 31158953. PMCID PMC7096228.
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. doi:10.1177/15563316251355551. PMID 40756949.
Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x. PMID 10469335.
Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. PMID 1999398.
Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004. PMID 16099219.
Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793. PMID 22074294.
Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. doi:10.1002/ibd.20334. PMID 18092346.
Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026. PMID 18061177.

Every source above studies a single compound. None of them tested GHK-Cu, BPC-157 and TB-500 as a combination.

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and how each batch is tested.

See GHK-Cu See KLOW Combo Certificates of analysis

General educational information only, research-use framing, not medical advice. The findings described are endpoints reported in published studies, in the systems those studies used, and are not promised outcomes. No dose or protocol is provided or implied here. Consult a qualified professional before acting.